Banham S W, Henderson A F, Bicknell S, Hughes J, Milroy R, Monie R D
Department of Respiratory Medicine, Royal Infirmary, Glasgow, U.K.
Respir Med. 1990 May;84(3):241-4. doi: 10.1016/s0954-6111(08)80042-x.
A single agent chemotherapy regimen, comprising epirubicin 120 mg m-2 iv at 21-day intervals for a maximum of six cycles was administered to 26 patients with intermediate or poor prognosis small cell lung cancer. Staging consisted of both conventional disease extent and prognostic guidelines based on laboratory parameters. The overall response rate was 57% which predominantly occurred among the intermediate prognosis group (14 of 17 patients), compared with only 1 of 9 patients in the poor prognosis category. Seven patients survived for at least 12 months, including one 3-year survivor (remains disease free). Chemotherapy toxicity was easily managed and chemoresponse was generally accompanied by an improvement in perceived performance rating. The study confirms the activity of epirubicin against small cell lung cancer and emphasizes the importance of patient selection within the spectrum of small cell lung cancer.
对26例预后中等或较差的小细胞肺癌患者采用单一药物化疗方案，即表柔比星120 mg/m²静脉注射，每21天1次，最多6个周期。分期包括传统的疾病范围和基于实验室参数的预后指南。总体缓解率为57%，主要发生在预后中等组（17例患者中的14例），而预后较差组9例患者中只有1例缓解。7例患者存活至少12个月，其中1例存活3年（无疾病复发）。化疗毒性易于处理，化疗反应通常伴随着体能状态评分的改善。该研究证实了表柔比星对小细胞肺癌的活性，并强调了在小细胞肺癌范围内进行患者选择的重要性。
